151
Participants
Start Date
March 31, 2011
Primary Completion Date
November 30, 2012
Study Completion Date
November 30, 2012
PRT-201
PRT-201 10 micrograms administered at the time of AVF creation.
Placebo
Placebo administered at the time of AVF creation.
PRT-201
PRT-201 30 micrograms administered at the time of AVF creation.
Weill Cornell Medical College, New York
Sentara Medical Group, Norfolk
Duke University Medical Center, Durham
Vanderbilt University Medical Center, Nashville
Indiana University, Indianapolis
University of Iowa, Iowa City
The Methodist Hospital, Houston
California Institute of Renal Research, San Diego
Kaiser Permanente, San Diego
UCSF, San Francisco
Rush Medical Center, Chicago
Renal Care Associates, Peoria
Indiana Ohio Heart, Fort Wayne
University of Louisville, Louisville
Vascular Specialty Center, Baton Rouge
Beth Israel Deconness Hospital, Boston
Brigham and Women's Hospital, Boston
UMASS Medical Center, Worcester
St Clair Specialty Physicians, Detroit
Thoracic & Cardiovascular Healthcare Foundation, Lansing
Montefiore Medical Center, The Bronx
Legacy Oregon Surgical, Portland
Lehigh Valley Hospital, Allentown
Lead Sponsor
Proteon Therapeutics
INDUSTRY